Loading...
Market
Will Immuneering announce completion of Phase 2b trial for IMM-1-104 by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Immuneering official announcements and clinical trial registries
Story
Immuneering ($IMRX) Announces Positive Phase 2a Data for Pancreatic Cancer Drug
Sep 14, 2024, 07:02 AM
Immuneering has announced positive initial Phase 2a data for its drug IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients. The data includes both complete and partial responses, indicating promising efficacy for the treatment. This development is a significant step forward in the fight against pancreatic cancer. The drug is listed under the ticker $IMRX.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
